Ratings MorphoSys AG

Equities

MOR

DE0006632003

Real-time Estimate Tradegate Other stock markets 07:20:44 2024-06-10 am EDT			5-day change	1st Jan Change
67.78 ^EUR	+1.31%		-1.17%	+99.56%

12:00am	MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	CI
Jun. 06	MorphoSys AG Announces Board Changes	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past four months, analysts' average price target has been revised upwards significantly.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+99.56%	2.72B	B-
MODERNA, INC.	+51.85%	57.87B	B-
LONZA GROUP AG	+41.53%	40.25B	A
IQVIA HOLDINGS INC.	-5.25%	39.94B	B
CELLTRION, INC.	-5.16%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B	B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B	C+
BIO-TECHNE CORPORATION	+0.61%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes